Tag
Early catheter ablation in atrial fibrillation patients with prior ischemic stroke reduces major adverse cardiovascular events and improves neurological and cognitive outcomes compared to medical therapy, according to a multi-center retrosp
The EMBOL-AF Global Registry provides comprehensive data on stroke and systemic embolism post-atrial fibrillation ablation, highlighting incidence, timing, risk factors, and procedural impacts alongside evolving ablation strategies and long
The ULYSSES trial demonstrates that ultrasound-guided femoral venous puncture markedly lowers vascular access complications compared to conventional palpation-guided techniques in patients undergoing atrial fibrillation ablation, enhancing
The InEurHeart trial demonstrates that computed tomography-guided ventricular tachycardia ablation significantly reduces procedure duration while maintaining safety and efficacy compared to conventional methods in patients with ischemic car
The PAM-VT 2 study reveals that cardiac MRI (LGE-CMR) performed 3 to 6 months after ventricular tachycardia ablation can accurately predict long-term recurrence risks by analyzing scar stability and conducting channels.
This review analyzes the STABLED trial findings alongside major AFib rhythm control studies, evaluating the efficacy and safety of catheter ablation added to DOAC therapy for secondary stroke prevention.
The CORECA study reveals that preprocedural 3D anatomic and substrate reconstruction from CT or MRI effectively identifies ventricular tachycardia targets in complex congenital heart disease, achieving 87.5% concordance with electroanatomic
The DARE-AF trial demonstrates that 10 mg of dapagliflozin for three months does not significantly reduce early arrhythmia recurrence or AF burden following catheter ablation in patients without existing indications for SGLT2 inhibitors.
The STABLED randomized clinical trial found that adding catheter ablation to standard edoxaban therapy did not significantly reduce the risk of recurrent stroke or composite cardiovascular outcomes in patients with atrial fibrillation and a
The NURSECAT-AF trial demonstrates that structured nurse-led care significantly improves quality of life and reduces arrhythmia recurrence and emergency visits by 80% in patients undergoing their first catheter ablation for atrial fibrillat
This large-scale real-world analysis reveals that GLP-1 receptor agonist therapy reduces atrial fibrillation recurrence by 18% and lowers all-cause mortality in obese patients following catheter ablation, highlighting a potent upstream stra
This real-world study demonstrates that GLP-1 receptor agonists significantly reduce AF recurrence, progression to permanent AF, and cardiovascular hospitalizations in obese patients following catheter ablation, highlighting their role as a
A post hoc analysis of the CABANA trial reveals that catheter ablation significantly reduces major cardiovascular events and improves quality of life in AF patients with high comorbidity burden (≥4 conditions), suggesting that multimorbidit
The WITHDRAW-AF trial suggests that heart failure therapy can be safely withdrawn in patients with atrial fibrillation-mediated cardiomyopathy who achieve rhythm control and ejection fraction normalization, showing no significant decline in
A clinical study demonstrates that catheter ablation is a highly effective rescue therapy for refractory, scar-related ventricular tachycardia occurring in the early phase of acute myocardial infarction, challenging traditional management t
The randomized CRRF‑PeAF trial (n=499) found cryoballoon pulmonary vein isolation non‑inferior to radiofrequency ablation for 1‑year atrial tachyarrhythmia recurrence in persistent atrial fibrillation, but radiofrequency produced greater le
In patients who underwent successful catheter ablation for atrial fibrillation at least one year earlier, rivaroxaban did not significantly reduce the composite of clinical or covert embolic stroke compared with aspirin over 3 years, while
This secondary analysis of the CABANA trial reveals catheter ablation significantly benefits AF patients with fewer than three nonmodifiable recurrence risk factors, underscoring the potential for personalized treatment strategies.
The ALONE-AF trial reveals that discontinuation of oral anticoagulants post-successful atrial fibrillation ablation may reduce stroke, systemic embolism, and major bleeding compared to continued therapy, informing anticoagulation strategies
